Australian clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) has updated investors to confirm that all patients dosed in the first cohort in the phase one CLTX CAR-T cell clinical trial have now advanced beyond the 28-day follow up period without experiencing dose-limiting toxicities. …
Chimeric updates on CLTX CAR-T cell clinical trial
April 22, 2021 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News